- X-ZELL announces the next-generation Cryoimmunostaining™ Suite
- The revolutionary multiplexing system will come with a more refined look, new controls and an updated cooling system under the brand’s signature red hood.
Singapore, June 2020 – 18 months after premiering at the 2019 Medlab Asia exhibition in Singapore, X-ZELL’s Cryoimmunostaining™ Suite is about to receive a facelift.
According to X-ZELL’s Head of Medical Devices, Bart Van der Voort, the next generation of the revolutionary multiplexing system will come with a more refined look, new controls and an updated cooling system under the brand’s signature red hood.
“When we first unveiled the Cryoimmunostaining™ Suite in March 2019, we didn’t know what to expect,” Van der Voort commented on the upgrade.
“In an industry dominated by traditional IHC staining and flow cytometry, we stepped onto the scene with a smart alternative promising the best of both worlds – we called it slide-based cytometry.
“We knew it had a lot of potential – given that we use it in our research centre on a daily basis – but nobody anticipated it to create such a buzz, especially because it went on sale for Research Use Only.”
Since the system’s first outing in Singapore, Van der Voort said X-ZELL’s Cryo-immunostaining™ technology has garnered interest from around the globe, with a special focus on haematology and leukaemia research.
“The option to simultaneously apply up to nine fluorophores to a sample without compromising on cell integrity has opened up a new world of research and routine diagnostic applications,” he explained – pointing out that uptake has been particularly strong in central Europe.
“It’s the perfect tool to ask complex research questions without wasting valuable sample material, so it’s caught attention among a very broad audience – which in turn helped us make subtle improvements over the past two years that will increase both user-friendliness and performance.”
According to Van der Voort, routine laboratories are now also starting to recognise the potential of the new system, which operates at sub-zero temperatures to safeguard the sample and has been pre-validated for wide array of standard fluorophores (see below).
“More and more routine laboratories are realising that they can save both time and money by consolidating panels on the Cryoimmunostaining™ system,” he said. “Many of them can self-certify these kind of applications as laboratory-developed tests (LDT) and instantly reap the reward – so there’s a lot of untapped potential for our system in that space.”
The facelift is part of a planned upgrade cycle, he added, and will replace the current generation from 1 August 2020.
Head of Strategy, Marketing & Communications
+65 9630 0706
About the X-ZELL Cryoimmunostaining™ Suite
Originally designed to enable X-ZELL’s own research into next-generation biomarkers, the Cryoimmunostaining™ Suite was spun off the company’s platform technology in March 2019 and has since been available as a standalone product.
Comprised of two patented devices, it permits researchers to stain suspended cells and cryosections with up to nine fluorophores at a time, compared to an industry average of three, which typically have to be applied in sequence.
Marketed for Research Use Only (RUO), the system is currently validated for 18 off-the-shelf fluorophores and their spectral equivalents, making for a vast spectrum of possible applications*.
The result is the world’s only multiplexed immunostaining system providing a genuine ‘plug & play’ solution – allowing researchers to solely focus on science instead of optimising the underlying hardware for each new application.
*compatible with suspended cells and cryosections, FFPE version under development. Currently validated for 18 fluorophores and their spectral equivalents, incl. DAPI, BV421, Pacific Blue, Pacific Orange, BV480, PerCp, AF488, PE, PE-Cy5, PE-Cy7, Propidium Iodide, AF594, DRAQ5, AF647, AF750, AF790, AF800, DIR.
About the Galen Growth HealthTech Cohort
X-ZELL is part of the Galen Growth HealthTech Cohort, the only acceleration programme built to scale digital health startups to be the next generation powering healthcare innovation in the New Normal in Asia. In 2020, Galen Growth is working with 25 HealthTech startups which will benefit from Galen Growth’s long-established and unmatched curated community of investors, corporate leaders and innovation teams and other essential stakeholders through our proven multi-channel tools. For more information, visit Galen Growth’s HealthTech Cohort webpage or read this article on the launch of the Galen Growth HealthTech Cohort.